Bringing target-matched PI3King from the bench to the clinic

@inproceedings{Janku2013BringingTP,
  title={Bringing target-matched PI3King from the bench to the clinic},
  author={Filip Janku},
  booktitle={Cell cycle},
  year={2013}
}
Increased signaling through the phosphoinositide 3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway occurs in diverse malignancies. In cancer, the PI3K/AKT/mTOR pathway can be activated by mutations in several oncogenes such as PIK3CA, PIK3R1, AKT, TSC1/2, LKB1 and PTEN (Fig. 1). Most activating mutations occur in the helical or kinase domain… CONTINUE READING